Work

Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Bessere klinische Ergebnisse mit iGlarLixi vs. BIAsp 30 in der SoliMix-Studie

Year: 2022

Type: article

Source: Diabetologie und Stoffwechsel

DOI: 10.1055/s-0042-1746275

Authors: Julio Rosenstock, Jochen Seufert, Rifat Emral, Leobardo Sauque Reyna, Viswanathan Mohan, Carlos Trescolí, Saud Al Sifri, Nebojsa Lalic, Agustina Alvarez, Pascaline Picard, Nacima Demil, Mireille Bonnemaire, Rory J. McCrimmon

Institutions: Dallas Diabetes Research Center, University Medical Center Freiburg, Ankara University, Dr. Mohan's Diabetes Specialities Centre, Hospital de La Ribera, Armed Forces Hospital, University of Belgrade, Univerzitetski Klinički Centar Srbije, Sanofi (Argentina), Sanofi (France), University of Dundee

Language: German

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286311967

FWCI:

Cites:

Cited by:

Related to: 10